Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

2005253 citationsJournal Articlebronze Open Access

Authors

Roel P.L.M. Hoogma · Groene Hart Ziekenhuis

Peter Hammond · Harrogate District Hospital

Ramón Gomis · Hospital Universitari de Vic

David Kerr · Royal Bournemouth Hospital

Daniela Bruttomesso · University of Padua

K.P. Bouter · Jeroen Bosch Ziekenhuis

K. Wiefels ·

Abstract

CSII usage offers significant benefits over NPH-based MDI for individuals with Type 1 diabetes, with improvement in all significant metabolic parameters as well as in patients' quality of life. Additional studies are needed to compare CSII with glargine- and detemir-based MDI.

Topics & Keywords

Diabetes Management and Research Diabetes Treatment and Management Diabetes and associated disorders

Publication Details

Published in: Diabetic Medicine

Volume 23, Issue 2, pp. 141-147

DOI: 10.1111/j.1464-5491.2005.01738.x

Field-Weighted Citation Impact: 7.45

Command Palette

Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH‐based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‐nations trial

Authors

Abstract

Topics & Keywords

Publication Details